Since the approval of the first gene therapy for blindness, there has been a wave of companies developing gene therapy treatments with the potential to cure different forms of genetic…
The biotech industry has often been criticized for its lack of gender diversity. While there is still a long way to go to achieve ideal levels of equality, there are…
Turning failure into success is a difficult but much needed skill in a high-risk industry such as biotech. At our latest Labiotech Refresh event, Christine Placet, now the CEO of…
Update (18/09/2018): Horama has increased the total raised in its Series B fundraising to €22.5M, with the Belgian fund V-Bio Ventures joining the team of investors backing the company. The…
French biotech Horama has treated the first patients with a gene therapy for retinitis pigmentosa that could prevent the progressive loss of vision caused by this genetic condition. A Phase…
Still catching up on news? We've picked out the most exciting things that happened besides clinical results and finance. Here's the biggest biotech news of 2017. We've been recapping the…
Horama has been authorized to start a Phase I/II trial in France testing HORA-PDE6B, a one-off gene therapy with the potential to cure retinitis pigmentosa. Based in Paris, Horama develops…
Horama is developing gene therapies for several hereditary retinal dystrophies. It has now raised €4M in its Series A round, which will speed up development of two candidates. Eye disorders…